clotrimazole (topical) (kloe-try-ma-zole)
Canesten, Clotrimaderm, Cruex, Lotriderm, Lotrimin
clotrimazole (vaginal) (kloe-try-ma-zole) Canesten, Clotrimaderm, Gyne-Lotrimin-3, Mycelex-7, Trivagizole-3
Therapeutic: antifungals (topical, vaginal)
Treatment of a variety of cutaneous fungal infections, including cutaneous candidiasis, tinea pedis (athlete's foot), tinea cruris (jock itch), tinea corporis (ringworm), and tinea versicolor. Treatment of vulvovaginal candidiasis.
Affects the permeability of the fungal cell wall, allowing leakage of cellular contents. Therapeutic Effects: Decrease in symptoms of fungal infection.
Adverse Reactions/Side Effects
Local: burning, itching, local hypersensitivity reactions, redness, stinging.
PHYSICAL THERAPY IMPLICATIONS
Examination and Evaluation
Avoid contact with cutaneous lesions when treating patient.
Always wash hands thoroughly and disinfect equipment (whirlpools, electrotherapeutic devices, treatment tables, and so forth) to help prevent the spread of infection.
Advise patient to report any increased local sensitivity to this drug (pain, burning, swelling).
Instruct patient about proper hygiene; e.g., thoroughly wash and dry the affected area, wear clean socks and ventilated shoes for tinea pedis, and so forth.
Advise patient to apply the drug as directed for the full course of treatment even if feeling better.
Inform patient that early relief of cutaneous symptoms may be seen in 2–3 days. Full therapeutic response may take 2 wk for cutaneous candidiasis, tinea cruris, and tinea corporis and 3–4 wk for tinea pedis.
Vaginal infections: therapeutic response is usually seen after 1 wk. Therapy should be continued during menstrual period.
Advise patient to seek medical help if infections persist or recur after the full treatment. Recurrent fungal infections may be a sign of systemic illness.
Absorption: Absorption through intact skin is minimal.
Distribution: Distribution after topical administration is primarily local.
Metabolism and Excretion: Systemic metabolism and excretion is negligible with local application.
Half-life: Not applicable.
|ROUTE ||ONSET ||PEAK ||DURATION |
|topical ||unknown ||unknown ||unknown |
|vaginal cream ||unknown ||8–24 hr ||unknown |
|vaginal tablet ||unknown ||1–2 days ||unknown |
Contraindicated in: Hypersensitivity to active ingredients, additives, preservatives, or bases.
Use Cautiously in: Nail and scalp infections (may require additional systemic therapy); patients with recurrent vulvovaginal yeast infections. OB/Lactation: Safety not established.
Topical (Adults and Children >3 yr): Apply cream or solution twice daily for 1–4 wk.